Skip to content

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial

Stefan Baumann, Robin Carhart-Harris, David Nutt, David Erritzøe, Balázs Szigeti

October 19, 2022 preprint DOI: 10.31234/osf.io/s4qhf (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Placebo-controlled citizen science trial
Sample size 240
Population Citizen scientists self-blinded in a microdose trial
Intervention psilocybin
Topics Psilocybin Microdosing
Keywords Microdose Blinding Placebo Post hoc Pharmacology Clinical trial
Citations 2
Key findings Correct microdose guess probability decreased with number of microdoses taken overall, indicating tolerance, but this tolerance was present only with LSD/LSD-analogue microdoses, not psilocybin microdoses.

Abstract

Microdosing is the practice of regularly using very low doses of psychedelic drugs. Anecdotal reports suggest that it may enhance well-being, creativity and cognition. Here, we use data from a self-blinding microdose trial, a large (n=240) placebo-controlled citizen science trial of microdosing to investigate whether tolerance develops during microdosing. We conceptualized tolerance as the relationship between correct microdose guess probability and the number of previous microdoses taken within the trial’s timeframe: if tolerance develops then, correct microdose guess probability should decrease with more microdoses taken. Mixed linear regression models show that correct microdose guess probability decreases with number of microdoses taken (mean±se: -.017±.007; p=.009**), suggesting that tolerance developed. Secondary post-hoc analysis revealed that this tolerance was present with LSD/LSD-analogue microdoses (mean±se: -.026±.007; p<.001**), but not with psilocybin microdoses (mean±se: .013±.014; p=.36). These results suggest that microdosers may need to periodically suspend their microdosing routine to avoid tolerance and that psilocybin may be better suited for long-term microdosing protocols.

Comparable studies

Other randomized controlled trials on psilocybin and microdosing, most cited first.

Study Year Design Participants
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study Individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis) 2022 Double-blind placebo-controlled experimental design n = 34
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study 2021 Randomized controlled trial
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study Participants in a microdosing workshop 2021 Preregistered combined field- and lab-based crossover study
Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity Individuals planning to microdose with psilocybin mushrooms 2021 Randomized controlled trial n = 34
Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials Participants in semi-naturalistic microdosing trials 2021 Double-blind placebo-controlled longitudinal trial (mega-analysis of three trials) n = 175

Explore topics

By condition and practice